E
Curis, Inc. CRIS
$2.18 -$0.015-0.69% NASDAQ
Recommendation
Prev Close
$2.19
Volume
43,461
Avg Vol (90D)
100,429
Market Cap
$18.59M
Dividend & Yield
--
52-Week Range
$1.02 - $16.93
P/E (TTM)
--
EPS (TTM)
-$7.03
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Curis files to sell 10.5M shares of common stock for holders
5/7/2025 - TipRanks Financial Blog
Curis files to sell 10.5M shares of common stock for holders
5/7/2025 - The Fly
Curis Inc (CRIS) Q1 2025 Earnings Call Highlights: Financial Improvements and Strategic Developments
5/7/2025 - GuruFocus
Q1 2025 Curis Inc Earnings Call Transcript
5/7/2025 - GuruFocus
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5/6/2025 - GuruFocus
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) CRIS Stock News
5/6/2025 - GuruFocus
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5/6/2025 - PR Newswire
Curis, Inc. (CRIS) Advances Emavusertib Studies with Positive Data
5/6/2025 - GuruFocus
Curis (NASDAQ:CRIS) Posts Quarterly Earnings Results
5/6/2025 - Ticker Report
Curis (NASDAQ:CRIS) Issues Earnings Results, Beats Expectations By $0.14 EPS
5/6/2025 - Ticker Report
Curis (CRIS) Strengthens Leadership with New Chief Medical Officer CRIS Stock News
5/6/2025 - GuruFocus
Curis Provides First Quarter 2025 Business Update
5/6/2025 - GuruFocus
Curis (CRIS) Expands Leadership and Advances Clinical Studies CRIS Stock News
5/6/2025 - GuruFocus
Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates
5/6/2025 - Zacks Investment Research
Curis Provides First Quarter 2025 Business Update CRIS Stock News
5/6/2025 - GuruFocus
Curis Inc (CRIS) Q1 2025 Earnings: EPS of -$1.25 Misses Estimates, Revenue of $2.4M Falls Short
5/6/2025 - GuruFocus
Curis reports Q1 EPS ($1.25), consensus ($1.26)
5/6/2025 - TipRanks Financial Blog
Curis appoints Ahmed Hamdy as Chief Medical Officer
5/6/2025 - TipRanks Financial Blog
Curis appoints Ahmed Hamdy as Chief Medical Officer
5/6/2025 - The Fly
Curis reports Q1 EPS ($1.25), consensus ($1.26)
5/6/2025 - The Fly
Curis Provides First Quarter 2025 Business Update
5/6/2025 - PR Newswire
Curis Inc (CRIS) Q1 2025 Earnings Report Preview: What To Expect
5/5/2025 - GuruFocus
Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline
5/1/2025 - Zacks Investment Research
Samsara BioCapital LLC Purchases New Shares in Curis, Inc. (NASDAQ:CRIS)
4/30/2025 - Ticker Report
Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and ...
4/29/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$10.91M
EBITDA (TTM)
-$44.34M
EBIT (TTM)
-$44.54M
Net Income (TTM)
-$43.39M
Balance Sheet
Total Assets (Q)
$41.27M
Total Debt (Q)
$37.13M
Total Liabilities (Q)
$47.26M
Book Value Per Share (Q)
-$0.7067
Cash Flow
Cash from Operations (TTM)
-$39.56M
Cash from Investing (TTM)
$29.44M
Cash from Financing (TTM)
$3.44M
Net Change in Cash (TTM)
-$6.68M
Filings
Filing Date
Monday, March 31, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
2.40
7-Day Total Return
16.94%
30-Day Total Return
-13.00%
60-Day Total Return
-32.45%
90-Day Total Return
-31.39%
Year to Date Total Return
-48.70%
1-Year Total Return
-86.57%
2-Year Total Return
-86.40%
3-Year Total Return
-87.24%
5-Year Total Return
-88.24%
52-week Low
Apr 09, 2025 - $1.02
52-week High
May 09, 2024 - $16.93
Valuation
Market Cap
$18.59M - Nano Cap
Enterprise Value
$35.72M
Price/Sales (TTM)
1.54
Price/Book (Q)
-3.10
Dividends and Shares
Shares Outstanding
7.67M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.curis.com
Phone Number
617 503 6500
Address
Building C
Suite 500 - 128 Spring Street
Lexington, MA 02421
Country
United States
Year Founded
2000
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates... more
NASDAQ 05/07/2025 1:51PM Eastern Quotes delayed